Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Enlivex Therapeutics Ltd.

Enlivex ( ($ENLV) ) just unveiled an announcement. On November 24, 2025, Enlivex Therapeutics Ltd. completed a $212 million private placement, mark...

Enlivex Completes $212 Million Private Placement, Expands Digital Asset Strategy

Antelope Enterprise Holdings, Enlivex Therapeutics, and Inno Holdings are the 3&nbsp;Penny Stocks&nbsp;to watch on November 25, 2025, based on&nbsp...

3 Penny Stocks to Watch Now, 11/25/25

The latest announcement is out from Enlivex ( ($ENLV) ). Enlivex Therapeutics Ltd. announced positive six-month topline data from the Phase IIa sta...

Enlivex Reports Positive Six-Month Data for Knee Osteoarthritis Trial

The latest announcement is out from Enlivex ( ($ENLV) ). On November 24, 2025, Enlivex Therapeutics Ltd. announced the completion of a securities p...

Market Cap	$24.78M	P/E Ratio	N/A
52W High	$2.10	52W Low	$0.83
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	N/A	52W Position	7.7%
Overall Score	24	Value Score	--
Quality Score	23	Technical Score	25

EPS Current Est	$-0.45	EPS Next Est	$-0.57
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ENLV	$0.93	-3.14%	922.08K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ENLV	$0.93	-3.1%	922.08K
3
4
5
6

ENLV

ENLV

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Enlivex Therapeutics Ltd. Data in Excel

Get Enlivex Therapeutics Ltd. Data in Excel